The following is a statement from Iffath Abbasi Hoskins, MD, FACOG, president of the American College of Obstetricians and Gynecologists, and Maureen G. Phipps, MD, MPH, FACOG, CEO of the American College of Obstetricians and Gynecologists.
“ACOG is grateful that the Supreme Court listened to the medical experts and has maintained access to safe, effective mifepristone. Even though mifepristone has remained available over the past several weeks, the ongoing judicial attacks have led to widespread chaos and confusion, with clinicians uncertain as to whether and where they could prescribe the medication for abortion and miscarriage management. Moreover, the inflammatory, biased language that pervaded the lower court decision instilled fear and falsehoods about medication abortion, the impact on patients, and the clinicians who provide compassionate abortion care.
“Although the Supreme Court has kept mifepristone available to patients for the duration of this legal battle, much of the damage of this process remains in place – and we know that the attacks on abortion care will not stop, no matter how many times medical professionals declare that abortion is essential, evidence-based health care and that interference in the patient-physician relationship must stop. We will continue to lead the medical community in providing the clear, strong evidence about mifepristone so that the Supreme Court can make the right decision in the end. ACOG remains steadfastly in opposition to interference in the patient-physician relationship.”